about
A novel Pfs38 protein complex on the surface of Plasmodium falciparum blood-stage merozoitesFc γ receptor IIIB (FcγRIIIB) polymorphisms are associated with clinical malaria in Ghanaian children.Malaria epidemiology in an area of stable transmission in tribal population of Jharkhand, IndiaConstruct design, production, and characterization of Plasmodium falciparum 48/45 R0.6C subunit protein produced in Lactococcus lactis as candidate vaccineDetermination of beta-defensin genomic copy number in different populations: a comparison of three methods.A randomized controlled phase Ib trial of the malaria vaccine candidate GMZ2 in African children.Polymorphisms in the RNASE3 gene are associated with susceptibility to cerebral malaria in Ghanaian childrenHigh-throughput tri-colour flow cytometry technique to assess Plasmodium falciparum parasitaemia in bioassays.Immunogenicity of the Plasmodium falciparum glutamate-rich protein expressed by vaccinia virusAntigenicity and immunogenicity of recombinant glutamate-rich protein of Plasmodium falciparum expressed in Escherichia coliNaturally acquired immune responses to malaria vaccine candidate antigens MSP3 and GLURP in Guahibo and Piaroa indigenous communities of the Venezuelan AmazonAntibodies to malaria vaccine candidates are associated with chloroquine or sulphadoxine/pyrimethamine treatment efficacy in children in an endemic area of Burkina Faso.Sero-epidemiological evaluation of changes in Plasmodium falciparum and Plasmodium vivax transmission patterns over the rainy season in Cambodia.Potential Impact of Seasonal Malaria Chemoprevention on the Acquisition of Antibodies Against Glutamate-Rich Protein and Apical Membrane Antigen 1 in Children Living in Southern Senegal.Transmission-blocking activity of antibodies to Plasmodium falciparum GLURP.10C chimeric protein formulated in different adjuvants.Recent advances in recombinant protein-based malaria vaccines.Antibody levels against GLURP R2, MSP1 block 2 hybrid and AS202.11 and the risk of malaria in children living in hyperendemic (Burkina Faso) and hypo-endemic (Ghana) areasHumoral immune response to Plasmodium falciparum vaccine candidate GMZ2 and its components in populations naturally exposed to seasonal malaria in EthiopiaA threshold concentration of anti-merozoite antibodies is required for protection from clinical episodes of malaria.Acquisition of natural humoral immunity to P. falciparum in early life in Benin: impact of clinical, environmental and host factors.Assessing malaria transmission in a low endemicity area of north-western Peru.Novel overlapping coding sequences in Chlamydia trachomatis.IgG reactivities against recombinant Rhoptry-Associated Protein-1 (rRAP-1) are associated with mixed Plasmodium infections and protection against disease in Tanzanian children.The GMZ2 malaria vaccine: from concept to efficacy in humans.Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine.Recognition of Plasmodium falciparum mature gametocyte-infected erythrocytes by antibodies of semi-immune adults and malaria-exposed children from Gabon.A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African children.A flow cytometry-based workflow for detection and quantification of anti-plasmodial antibodies in vaccinated and naturally exposed individuals.Reduced antibody responses against Plasmodium falciparum vaccine candidate antigens in the presence of Trichuris trichiura.Naturally acquired antibody responses to recombinant Pfs230 and Pfs48/45 transmission blocking vaccine candidates.A Plasmodium falciparum 48/45 single epitope R0.6C subunit protein elicits high levels of transmission blocking antibodies.Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations.A multi-stage malaria vaccine candidate targeting both transmission and asexual parasite life-cycle stages.Naturally Acquired Antibodies Target the Glutamate-Rich Protein on Intact Merozoites and Predict Protection Against Febrile Malaria.Natural antibody responses to Plasmodium falciparum MSP3 and GLURP(R0) antigens are associated with low parasite densities in malaria patients living in the Central Region of Ghana.Antibody responses to two new Lactococcus lactis-produced recombinant Pfs48/45 and Pfs230 proteins increase with age in malaria patients living in the Central Region of Ghana.Expression, Purification and Characterization of GMZ2'.10C, a Complex Disulphide-Bonded Fusion Protein Vaccine Candidate against the Asexual and Sexual Life-Stages of the Malaria-Causing Plasmodium falciparum Parasite.Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display.Synthetic TLR4 agonists enhance functional antibodies and CD4+ T-cell responses against the Plasmodium falciparum GMZ2.6C multi-stage vaccine antigen.Is Fc gamma receptor IIA (FcγRIIA) polymorphism associated with clinical malaria and Plasmodium falciparum specific antibody levels in children from Burkina Faso?
P50
Q30038987-A68FC95B-CA3E-4680-9D69-07773C044E17Q31104503-BFA11561-8D27-4D29-AB5D-A9A10EF42086Q33629755-FC656F9B-870F-4956-B443-5876CBDA88C1Q33750638-759432A2-6817-4F6C-A221-E43F1C454905Q33833931-221E3720-DE5A-4EAE-9D9D-F33E8A0D9065Q33987686-096E6335-6FC5-4EC3-9BC6-ACA87DA0426AQ34117608-E229C6DB-AA2D-4FB4-9750-78C5C7B8ED64Q34423023-320251EF-D93A-48A4-BD6F-5DCD63820E0AQ34533068-2D4789F9-FEB3-4245-9747-7EBC58977316Q35223977-B1023E15-50BE-4D13-A167-F7FC6802A233Q35812148-8D62F5D4-E36F-4144-ACDF-C44EF6779FA9Q35917797-6FA48897-4B9F-4362-9732-E9EA308747DAQ35998522-80492211-948D-4965-B7BD-EA25282CDEDEQ36132032-3C72D4A8-96D0-4E5D-9CE7-937DABBC7597Q36267184-A884915E-5ADD-42F3-A463-C8F3151787DEQ36394182-47576F0A-3AC4-42DD-B64A-20947F55B4C1Q36625461-33D3351C-49FC-478E-A6DE-665DD19C5727Q36741193-C4E1FED7-8E4F-45FC-88C9-3B21CDF5882AQ37148056-7846BC90-9E2E-421B-B601-E6287E6E9836Q37285306-B53DB15C-FA36-4A8C-AFD2-9E52B3A19E71Q37361179-BEE9DFCF-9B00-41EB-A337-AC81A44C8953Q37861208-E26AE7AA-0D16-47BD-940E-EA7EAB2DDBA4Q38527035-2EADAFAF-2228-4071-8C62-D46D961E625CQ38658724-8163CA87-2E7F-4D30-84D7-60344E4BB039Q38775588-09711360-8956-4FC3-AF5D-53ABE86C76DCQ38818196-092CE7B2-85B6-4147-A214-993D34FF31B7Q38853596-6B90DE11-EE38-4694-A3C6-0DB747DBAB93Q38864802-F2201209-7223-462E-99E7-E8BC59E9E528Q38995073-56AF0956-0775-48E7-9F1C-3A4C261F09D3Q39018502-DD5C11CC-007F-4E2A-AA49-D0355D5CB0A0Q39467691-6501AC6D-8685-47A4-A9F7-943EE774F42EQ39507822-F06E7B6A-9631-49FF-8BAD-322A26B10F1AQ39520295-F789D487-FFA5-423F-9C64-162B047315D6Q40064367-5D6642DA-D70D-49E1-96A8-2E84DDBA2DF8Q40082177-55899B3E-6C0F-4C9C-8806-FE065D68AA4CQ40110842-62C83A87-AD4A-48E7-AA3E-3B59C0A136E2Q40159945-965D403D-F8A4-442C-946B-5725F0485498Q40173704-91B337E1-EF65-4BD8-A0ED-511CC93EB944Q40749062-82F0226D-9612-465A-BE6F-E7B9F751B9E5Q41635798-CE3FD68D-5924-4535-B7B7-4C1D094513D2
P50
description
researcher, ORCID id # 0000-0003-4412-1392
@en
wetenschapper
@nl
name
Michael Theisen
@ast
Michael Theisen
@en
Michael Theisen
@es
Michael Theisen
@nl
type
label
Michael Theisen
@ast
Michael Theisen
@en
Michael Theisen
@es
Michael Theisen
@nl
prefLabel
Michael Theisen
@ast
Michael Theisen
@en
Michael Theisen
@es
Michael Theisen
@nl
P214
P106
P1153
7005561427
P21
P214
P31
P496
0000-0003-4412-1392
P735
P7859
lccn-n96111532